Immunovant slips as investors keep discounting batoclimab after Phase 3 TED miss
Immunovant shares fell 3.51% to $27.30 on April 28, 2026, extending weakness after the company’s Phase 3 thyroid eye disease (TED) trials missed primary endpoints earlier this month. The move appears driven by ongoing risk-off positioning and profit-taking, with no new company press release or SEC filing posted today.
1) What’s moving the stock today
Immunovant (IMVT) traded down 3.51% to $27.30 on Tuesday, April 28, 2026, in a continuation move rather than a reaction to a fresh headline. A review of the company’s investor press-release feed shows no new corporate announcement posted today, pointing to sentiment and positioning as the primary drivers. (immunovant.com)
2) Overhang: Phase 3 thyroid eye disease miss still in focus
The biggest recent fundamental catalyst remains the company’s disclosure that its Phase 3 GO trials of batoclimab in thyroid eye disease failed to meet primary endpoints, which has pressured expectations for that program and kept investors focused on pipeline execution risk. With no new offsetting catalyst today, shares are seeing incremental selling as the market continues to digest the implications of that readout. (finance.yahoo.com)
3) What to watch next
Near-term attention is shifting to upcoming clinical milestones for IMVT-1402 and to the next scheduled earnings event window in early June 2026, when investors will look for updated timelines, cash runway commentary, and any changes in development prioritization following the TED outcome. (tipranks.com)